Company Description
EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases.
The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.
Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic macular edema (DME).
The company’s pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases.
The company was formerly known as EyePoint Pharmaceuticals, Inc. and changed its name to EyePoint, Inc. in December 2025.
EyePoint, Inc. was founded in 2000 and is headquartered in Watertown, Massachusetts.
| Country | United States |
| Founded | 1987 |
| IPO Date | Jan 27, 2005 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 214 |
| CEO | Jay Duker |
Contact Details
Address: 480 Pleasant Street, Suite C-400 Watertown, Massachusetts 02472 United States | |
| Phone | 617 926 5000 |
| Website | eyepoint.bio |
Stock Details
| Ticker Symbol | EYPT |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001314102 |
| CUSIP Number | 30233G209 |
| ISIN Number | US30233G2093 |
| Employer ID | 26-2774444 |
| SIC Code | 3826 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jay S. Duker M.D. | President, Chief Executive Officer and Director |
| George O. Elston CPA | Executive Vice President and Chief Financial Officer |
| Dr. Ramiro Ribeiro M.D., Ph.D. | Chief Medical Officer |
| Dr. Marcia Sellos-Moura Ph.D. | Chief Scientific Officer |
| Ron I. Honig Esq. | Chief Legal Officer and Company Secretary |
| Jennifer Leonard | Chief People Officer and Senior Vice President of IT |
| David Scott Jones M.A. | Senior Vice President |
| Isabelle Lefebvre | Chief Regulatory Officer |
| Michael J. Maciocio | Chief Manufacturing Officer |
| Michael Campbell | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 27, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 27, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 17, 2026 | 144 | Filing |
| Apr 13, 2026 | 8-K | Current Report |
| Mar 26, 2026 | SCHEDULE 13G/A | Filing |
| Mar 20, 2026 | 8-K | Current Report |
| Mar 5, 2026 | 10-K | Annual Report |
| Mar 4, 2026 | 8-K | Current Report |
| Mar 2, 2026 | 8-K | Current Report |
| Feb 24, 2026 | SCHEDULE 13G | Filing |